stroke
Label
Peptic Ulcer Disease

DefinitionEtiologyEpidemiologyPathophysiologyClinical Presentation
WorkupGoalsMed ChoicesClinical TrialsPipeline AgentsResourcesRefs
Definition:

Erosion of the gastrointestinal mucosa extending through muscularis mucosa, involving the stomach (gastric ulcer), and duodenum (duodenal ulcer).

 

Back to Top
Etiology:

Common causes:

  • Helicobacter pylori (H. pylori) infection
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)

Less common causes:

  • Other drugs may include steroids, bisphosphonates
  • Carcinoid syndrome
  • Post-gastric surgery
  • Chronic renal failure
  • Radiation/chemotherapy
  • Zollinger-Ellison syndrome
  • Crohn's disease
  • Ischemia, usually related to crack cocaine use

Risk factors:

  • Smoking/stress
  • Diabetes mellitus
  • Cirrhosis

 

Back to Top
Epidemiology:
  • Annual incidence of PUD ranges from 0.1-0.3%
  • Incidence increases with age
  • Incidence in H. pylori-infected individuals is ~1% per year
  • 70% of ulcers occur between ages 25 and 64 years
  • No predilection by gender
  • First-degree relatives of patients with duodenal ulcer (DU) have a threefold increase in the prevalence of DU but not gastric ulcer (GU)
  • Lifetime prevalence is 8-14%; 20% higher in H. pylori positive subjects
  • Mortality rate is approximately 1 death per 100,000 cases
  • Hospitalization rate is 30 patients per 100,000 cases

 

Back to Top
Pathophysiology:

Parietal cells of stomach produce acid and decrease pH, which in turn causes release of somatostatins leading to inhibition of acid secretion (by negative feedback control)..

Within the acidic environment of the stomach, the mucosa is protected by several mechanisms as follows:

  • Production of mucus and HCO3 where mucus serves as a barrier to acid diffusion
  • Epithelial cells remove excess H+ ions and prevent back diffusion
  • Mucosal blood flow removes excess acid
  • Growth factors and prostaglandins are shown to have protective effects

Factors that interfere with these mucosal defenses (particularly NSAIDs and Helicobacter pylori infection) predispose to gastritis and peptic ulcer disease.

NSAIDs cause mucosal inflammation and ulcer formation by:

  • Inhibiting prostaglandin production by blocking enzyme cyclooxgenase (COX)
  • Reduce gastric blood flow causing decrease cell repair and replication
  • They are weak acids, diffuse freely across the mucus membrane, liberating H+ ions leading to cellular damage

Helicobacter pylori: Interferes with mucosal physiology. Mechanisms include

  • Increase acid secretion (combination of increase in acid secretions and decrease in duodenal bicarb secretion resulting low pH)
  • Gastric metaplasia (promoted by increased acid secretion)
  • Alters immune responses leading to persistent colonization
  • H. pylori colonization in duodenum induces inflammation and reduces bicarb secretion thus promoting ulcer formation
  • Diminishes mucosal defense mechanism

 

Back to Top
Clinical Presentation:

General symptoms:

  • Epigastric pain
  • Dyspepsia
  • ± Nausea/vomiting
  • Symptom free periods (months to years), alternate with the symptomatic periods

Other less common symptoms/complications:

  • Hematemesis
  • Melena
  • Weight loss
  • Anorexia
  • Syncope

GU: Recurrent burning or gnawing pain in the epigastrium (not related to food), heartburn, early satiety and radiation of pain to the xiphisternum.

DU: Consistent pain, which may awake the patient in the night, related with food (subsides in 50% with food intake, but recur after 2-3 hrs).

1-b-Black-Light box-PU-Clinical Presentation-Comparison

 

Back to Top
Investigation and Workup:

HISTORY:

History of pain includes:

  • Intensity/location
  • Nature of pain (burning, squeezing)
  • Radiating or non-radiating
  • Association with meals or nausea/vomiting
  • Association with chest discomfort

 

EXAMINATION:

  • Epigastric tenderness may or may not be present

 

LABORATORY:

Lab tests to consider when evaluating PUD:

  • CBC, LFTs to exclude anemia and gall stones
  • Serum amylase and lipase to assess for pancreatitis
  • Cardiac enzymes (rule out myocardial ischemia in acute presentation)

Other lab tests that may be required are:

  • Helicobacter pylori serology
  • Serum gastrin to rule out Zollinger-Ellison syndrome
  • Gastric fluid analysis to rule out acid hypersecretion

 

IMAGING STUDIES

Upper gastrointestinal radiography series:

  • Indicated when endoscopy is unsuitable or not feasible
  • Relatively low sensitivity and specificity
  • Avoid in the patient with upper GI bleeding

1-Black-Light box-PU-Investigation and workup-Benign versus Malignant lesions on x-rays

 

Esophagogastroduodenoscopy (endoscopy):

Most reliable diagnostic test for PUD

Indications for endoscopy include:

  • Patient >50 years with new-onset dyspepsia
  • Symptoms of bleeding, weight loss, dysphagia
  • Refractory or persistent abdominal pain
  • Suspicion of upper GI abnormality (mass, stricture, ulcers etc.)
  • Diagnosis of an H. pylori infection when non-invasive testing is not possible

2-Black-Light box-PU-Investigation and workup-Benign versus Malignant lesions on endoscopy

 

Indications and diagnostics for screening H. pylori infections in patients with dyspepsia

Indications:

  • History of dyspepsia
  • Active or uncomplicated peptic ulcer disease
  • Gastric MALT (mucosa associated lymphoid tissue) lymphoma
  • Recent bleeding in PUD patients
  • Patients who are first degree relatives of gastric cancer patients
  • Patients with idiopathic thrombocytopenic purpura (ITP)
  • Patients with otherwise unexplained iron deficiency anemia

Noninvasive diagnostics:

  • Serology: ELISA techniques detect IgG antibodies (sensitivity ~60-90%)
  • Urea breath test (UBT): Sensitivity and specificity is about >90%
    • Discontinue proton pump inhibitors or H2 receptor antagonists, antibiotics and bismuth 4 weeks before a test based on H. pylori urease production
  • Stool antigen test (SAT): Sensitivity 91% and specificity 93%

Invasive diagnostics:

Endoscopy:

  • Biopsy (gold standard): 95% sensitive / 100% specific / results in 24 hrs
  • Rapid urease test: 95% sensitive / 95% specific / results in 1 hr

Additional Biopsy consideration and sample evaluation:

  • Brush cytology: Considered in patients with bleeding disorders; where biopsies are considered undesirable
  • Histology helps in distinguishing inflammation, metaplasia and MALT
  • Polymerase chain reaction (PCR) used only when ordinary culture cannot be done

Confirmation of eradication should be strongly considered and assessed through noninvasive tests (stool and breath tests).

 

Back to Top
Treatment Goals:
  • Avoid hypervolemia
  • Relieve pain and reduce anxiety
  • Relieve dyspepsia and heal the ulcer
  • Prevent complications, e.g. bleeding, perforation
  • Prevent recurrence and maintain nutrition
  • Remind patients to discuss the biopsy reports with their primary care giver
  • Community pharmacists should urge the patients to remind their family physicians to follow up on results post treatment
  • Provide information about the management and prevention of recurrence of ulcers

 

Back to Top
Therapeutic Choices:

Peptic ulcer disease is treated according to its cause:

  • H. pylori associated ulcer
  • NSAIDs associated ulcers
  • Refractory ulcers

1) H. PYLORI ASSOCIATED ULCERS:

Goal is to relieve dyspepsia, promote healing and cure infection.

Uncomplicated ulcers are treated for 10-14 days, provided ulcer is <1cm and dyspepsia resolves; treatment options are as follows:

1st Line Therapy (eradication rates 70-85%):

Combination of:

PPIs:

  • Pantoprazole 40 mg PO BID, omeprazole 20 mg PO BID or rabeprazole 20 mg PO BID or lansoprazole 30 mg PO BID are few examples

Macrolide:

  • Clarithromycin 500 mg PO BID

Penicillin:

  • Amoxicillin 1 gm PO BID (if penicillin allergic give metronidazole 500 mg PO BID)

2nd Line Therapy (eradication rates 75-90%):

  • PPIs PO BID (as mentioned above) PLUS
  • Bismuth subsalicylate 2 tabs PO QID PLUS
  • Tetracycline 500 mg PO QID PLUS
  • Metronidazole 250 mg PO QID

OR the combine formulation of:

  • Pylera 3 capsules PO QID which is a combination of (Bismuth + Tetracycline + Metronidazole)

3rd Line Therapy (reports of eradication rates vary):

  • PPIs PO twice daily (as mentioned above) PLUS
  • Day 1-5: Amoxicillin 1 gm PO daily PLUS
  • Day 6-10: Clarithromycin 500 mg and metronidazole 500 mg, both twice daily

Complicated ulcers or ulcers >1cm: Antisecretory agent should be given for additional 2-4wks in duodenal ulcers and 4-6wks in gastric ulcers.

Note: Confirm eradication after >4 wks of completion of therapy by invasive or non-invasive methods.

2) NSAID-ASSOCIATED ULCERS:

Active ulcers: ADiscontinue offending agents if possible.

Treatment options:

PPIs:

  • Pantoprazole 40 mg PO BID, omperazole 20 mg PO BID or rabeprazole 20 mg PO BID or lansoprazole 30 mg PO BID are few examples
  • Duodenal ulcers (uncomplicated) treated for 4 weeks
  • Gastric ulcers (uncomplicated) treated for 8 weeks
  • For complicated ulcers PPIs are preferred drugs

H2 receptor antagonists:

Uncomplicated duodenal ulcers:

  • Cimetidine 800 mg or ranitidine or nizatidine 300 mg or famotidine 40 mg PO daily at bedtime for 6 weeks

Uncomplicated gastric ulcers:

  • Cimetidine 400 mg or ranitidine or nizatidine 150 mg or famotidine 20 mg PO twice daily for 8 weeks

 

3) PREVENTION AND MAINTENANCE:

A) High risk patients related to NSAID induced ulcer requiring prophylactic therapy include:

  • History of ulcers
  • Complicated ulcers
  • Current use of steroids or anticoagulants/antiplatelet agents
  • Age >60 years
  • Serious comorbid illness

Treatment Options:

  • PPIs
  • Change patient to COX-2 selective NSAID (contraindicated in patients with risk of CVD)
  • Misoprostol

B) Long term maintenance therapy is indicated in patients with recurrent ulcers who are H. pylori negative or have failed attempts of eradication.

Treatment Options:

  • PPIs
  • H2 receptor antagonist at bedtime

C) Non-pharmacological therapy includes:

  • Quit smoking
  • Avoid excess alcohol
  • Dietary modification
  • Adequate rest
  • Compliance with drug therapy and long-term follow-up care (as required)

 

4) COMPLICATIONS OF PEPTIC ULCER:

Perforation presents with (medical emergency)

  • Severe sudden abdominal pain
  • Rigidity
  • Abdominal distension

Treatment options:

  • Simple closure
  • Graham patch with or without a laparoscopic vagotomy (for duodenal ulcers)
  • Truncal vagotomy with pyloroplasty (incorporating the perforation)
  • Preferred approach for gastric ulcers in elderly is partial gastrectomy

Bleeding

  • Hemodynamic instability
  • Hematemesis/hematochezia/melena

- Initial management

  • Resuscitation
  • Medical therapy with intravenous proton pump inhibitors
  • Rapidly correct coagulopathy with blood products
  • Endoscopic intervention
    • Injection therapy (options):
      • Epinephrine injection
      • Saline injection (to tamponade bleeding vessel)
      • Fibrin sealant or other injection sclerotherapy
    • Note: While various agents have been used to help control bleeding a key feature of injection therapy, regardless of agent, is essentially to tamponade the bleeding vessel. The use of sclerosants may be complicated by perforations and are usually discouraged.
    • Thermal coagulation: May be achieved through direct contact devices (e.g. heater probes, electrocoagulation) and noncontact devices (argon plasma coagulation, APC), which appear to have similar efficacy
    • Endoclips/Hemoclips: May have the distinct advantage of lowering rate of recurrent bleeding as compared to other therapies, but are difficult to apply and so cannot always be utilized
    • Combination therapy: Diluted epinephrine injection followed with thermocoagulation may be a useful approach particularly in high risk patients

- Indications for surgery

  • Hemodynamic instability despite vigorous resuscitation (>3 unit transfusion)
  • Shock associated with recurrent hemorrhage
  • Failure to arrest hemorrhage on endoscopy
  • Recurrent bleeding despite endoscopic attempts at achieving hemostasis

Surgical procedures

  • Duodenal ulcers: First ligation of gastroduodenal artery at the superior and inferior aspect of the ulcer is done then pyloroplasty possibly combined with truncal vagotomy
  • Gastric ulcers: Resection with Billroth I or II reconstruction

Penetration

  • Penetration through the bowel wall without perforation and leakage of luminal contents into the peritoneal cavity
  • 20% of ulcers penetrate
  • Presents with gradual or sudden change in symptoms
  • Gastrocolic fistulae are seen with greater curvature gastric ulcers

Treatment

  • Managed with intensive ulcer treatment regimens
  • Surgical options can also be considered

Obstruction

  • Early satiety and bloating
  • Indigestion/epigastric pain
  • Anorexia/weight loss
  • Nausea and vomiting of recognizable food
  • Dehydration/metabolic alkalosis

Treatment

Gastric outlet obstruction is usually not an emergency

Stabilize patient then consider:

  • Nasogastric tube decompression
  • Correction of fluid and electrolyte
  • Preoperative nutritional supplementation
  • Full dose intravenous antisecretory therapy
  • Endoscopic balloon dilatation
  • Surgical options are:
    • Truncal vagotomy and gastrojejunostomy
    • Antrectomy (rarely performed)
    • Distal gastrectomy, combined with vagotomy

 

Medications:

H2-Receptor Antagonist (H2RA)

  • Cimetidine
  • Ranitidine
  • Famotidine
  • Nizatidine

MECHANISM:

Inhibits the histamine at H2 receptors of the gastric parietal cells, resulting in decreased secretion of gastric acid.

DOSE:

Cimetidine

  • Oral: 400 mg BID or 800 mg once daily
  • strong>IV / IM: 300 mg every 6hrs; Dilute for IV route

Dose in renal insufficiency:

  • Decrease dose by 50% if ClCr 10-50 mL/min
  • Decrease dose by 75% if ClCr <10 mL/min

Ranitidine

  • Oral: 150 mg BID or 300 mg once daily
  • IV / IM: 50 mg every 6-8 hrs; dilute for IV route

Dose in renal insufficiency:

  • 150 mg PO daily; if ClCr <50 mL/min

Famotidine

  • Oral: 20 mg BID or 40 mg daily
  • IV: 20 mg every 12 hrs

Dose in renal insufficiency:

  • Decrease dose by 50% if ClCr <50 mL/min

Nizatidine

  • Oral: 150 mg BID or 300 mg daily

Dose in renal impairment:

Active treatment:

  • Clcr 20-50 mL/minute: 150 mg/day
  • Clcr <20 mL/minute: 150 mg every other day

Maintenance treatment:

  • Clcr 20-50 mL/minute: 150 mg every other day
  • Clcr <20 mL/minute: 150 mg every 3 days

 

Proton Pump Inhibitors (PPIs)

  • Omeprazole
  • Lansoprazole
  • Esomeprazole
  • Rabeprazole
  • Pantoprazole

MECHANISM:

Suppress gastric acid secretion by inhibition of the gastric enzyme H+/K+-ATPase in the gastric parietal cell.

DOSE:

Omeprazole

  • 20 mg PO once daily for 4-8 wk.; in refractory patients 40 mg PO daily

Lansoprazole

  • Duodenal ulcer: 15 mg PO daily for ~4 wk
  • Gastric ulcer: 30 mg PO daily for ~8 wk
  • IV: 30 mg IV daily over 30 min

Esomeprazole

  • Oral: 20-40 mg daily for 4-8 wk
  • IV: 20-40 mg daily

Rabeprazole

  • 20 mg PO daily for 4-6 wk

Pantoprazole

  • 40 mg PO daily for 4-8 wk

 

Gastroduodenal Cytoprotective Agent-Antacids

  • Sucralfate

MECHANISM:

Produces an adherent and cytoprotective barrier at the ulcer site by binding with positively charged proteins in exudates, forming a protective coat for ulcer site against peptic acid, pepsin and bile.

DOSE:

Sucralfate

Peptic ulcer

  • 1 g PO QID, an hour before meals and at bedtime, on an empty stomach for 4-8 weeks

Duodenal ulcer

  • 2 g PO BID on waking up and at bedtime on an empty stomach for 4-8 weeks

Duodenal ulcer maintenance/prophylaxis

  • 1 g PO BID on an empty stomach

 

Mucosal Protective Agent

  • Misoprostol

MECHANISM:

It is a synthetic analog of prostaglandin E1.

  • It replaces the protective prostaglandins that have been depleted due to prostaglandin-inhibiting therapies (e.g. NSAIDs) and also inhibits the acid production
  • It also induces uterine contractions and exhibit a significant cervical priming effect

DOSE:

Misoprostol

Duodenal ulcers/Prevention of NSAID-induced ulcers

  • 200 mcg PO QID with food and fourth dose taken at bedtime; if not tolerated, may decrease dose to 100 mcg QID or 200 mcg BID

Note: Administer for the duration of NSAID therapy

 

H. Pylori Eradication Regimen:

➢ PPI + Amoxicillin + Clarithromycin

 

➢ PPI + Metronidazole + Clarithromycin

 

➢ PPI + Amoxicillin + Metronidazole

 

➢ PPI + Bismuth subsalicylate + Metronidazole +

Tetracycline

 

➢ PPI + Amoxicillin followed by PPI + Clarithromycin +

Metronidazole

 

  • Triple therapy (oral): 2 antibiotics plus a PPI for 14 days
    1. PPI (standard therapy) PO BID PLUS
    2. Amoxicillin 1 g PO BID OR Metronidazole 500 mg PO BID PLUS
    3. Clarithromycin 500 mg PO BID
  • Alternative triple therapy regimen: if clarithromycin resistance is present:
    1. PPI (standard therapy) PO BID PLUS
    2. Amoxicillin 1 g PO BID PLUS
    3. Metronidazole 500 mg PO BID
  • Alternative triple therapy regimen: if penicillin allergic:
    1. PPI (standard therapy) PO BID PLUS
    2. Clarithromycin 500 mg PO BID PLUS
    3. Metronidazole 500 mg PO BID
  • Alternative Quadruple Therapy regimen:
    1. PPI (standard therapy) PO BID PLUS
    2. Bismuth subsalicylate 2 tabs PO QID PLUS
    3. Metronidazole 250 mg PO QID plus
    4. Tetracycline 500 mg PO BID

Sequential therapy

  • PPIs PO BID (as mentioned above) PLUS
  • Day 1-5: Amoxicillin 1 gm PO daily PLUS
  • Day 6-10: Clarithromycin 500 mg and metronidazole 500 mg, both twice daily

 

Back to Top
Clinical Trials:
Back to Top
Pipeline Agents:

Pending new data.

 

Back to Top
Pharmacist Resources:

Encourage

  • Patient to minimize smoking and alcohol consumption
  • Avoid circumstances leading to physiological stress (stress is related to increased acid secretions in stomach and it has been shown that H. Pylori thrives to grow in acidic medium)
  • Educate patient about
    • PUD symptoms and therapy
    • To use moderation if a food or beverage makes dyspepsia worse
    • To follow up any test results with physician (e.g. biopsies from endoscopy)

Drugs

  • Evaluate cost, affordability and insurance coverage for patients
  • Some PPIs are as much as 40% less costly than others
  • Whenever possible alternatives of salicylates and NSAIDs (COX2 inhibitors) should be used

Unlabeled/Alternate uses include but not limited to:

  • Misoprostol
    • Cervical ripening
    • Labor induction
  • Sucralfate
    • Stomatitis
    • Esophagitis

Counseling

  • Ensure patient is well informed about disease and its treatment
  • Discuss strategies to quit smoking
  • Common offenders for dyspepsia are coffee, orange juice, spicy foods, fatty foods, large meals or eating on the run
  • For patients using NSAIDs, discuss the risk of NSAID-induced gastric complications
  • Teach patient signs and symptoms of bleeding and when to notify the health care provider

Alerts

  • Follow-up endoscopy must be performed in GU pts to avoid the rare initial misdiagnosis of a gastric cancer
  • Presence of multiple ulcers in distal duodenum and jejunum or refractory ulcers raise possibility of Zollinger-Ellison syndrome (ZES)

Tips

  • Smoking cessation improves ulcer healing and reduces recurrence of ulcers not related to H. pylori infection
  • Peptic ulcer caused by ASA or NSAIDs are usually painless
  • Repeat testing by UBT or endoscopic biopsies to prove eradication is necessary in patients with a complicated ulcer

Expected outcome

  • With successful treatment, prognosis is excellent
  • Risk of rebleeding, NSAID ulcer recurrence, and ulcer relapse rate are decreased after H. pylori eradication

2. Scales and Tables

 

Back to Top
References:

Core Resources:

  • Compendium of Pharmaceuticals and Specialties (CPS). Canadian Pharmacist association. Toronto: Webcom Inc. 2012
  • Day RA, Paul P, Williams B, et al (eds). Brunner & Suddarth's Textbook of Canadian Medical-Surgical Nursing. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2010
  • Foster C, Mistry NF, Peddi PF, Sharma S, eds. The Washington Manual of Medical Therapeutics. 33rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010
  • Gray J, ed. Therapeutic Choices. Canadian Pharmacists Association. 6th ed. Toronto: Webcom Inc. 2011
  • Holbrook AM (Chair) for Ontario GI Therapy Review Panel. Ontario Guidelines for Peptic Ulcer Disease and Gastroesophageal Reflux. Toronto. First Edition. Queen's Printer of Ontario, 2000
  • Hurst's the Heart Manual of Cardiology, 12th Edition
  • Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. 11th ed. New York: McGraw-Hill; 2009
  • Longo D, Fauci A, Kasper D, et al (eds). Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2011
  • McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 49th ed. New York: McGraw-Hill; 2010
  • Pagana KD, Pagana TJ eds. Mosby's Diagnostic and Laboratory Test Reference. 9th ed. St. Louis: Elsevier-Mosby; 2009
  • Skidmore-Roth L. ed. Mosby's drug guide for nurses. 9th ed. St. Louis: Elsevier-Mosby; 2011
  • Skidmore-Roth L, ed. Mosby's nursing drug reference. 24th ed. St. Louis: Elsevier-Mosby; 2011

 

Online Pharmacological Resources:

  • e-Therapeutics
  • Lexicomp
  • RxList
  • Epocrates

 

Journals/Clinical Trials:

  • Bhatt DL, Cryer BL, Constant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease N Engl J Med 2010; 363:1909-1917
  • Chan FKL, To KF, Wu JCY et al. outline goes here Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. The Lancet, 2002 ;(359), pgs.9-13
  • Khuroo MS, Yattoo GN, Javid G et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 1997;336(15):1054-8
  • Kubba AK, Palmer KR. Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Br J Surg 1996; 83:461
  • Lai KC, Hui WM, Wong BC, et al. A retrospective and prospective study on the safety of discharging selected patients with duodenal ulcer bleeding on the same day as endoscopy. Gastrointest Endosc. 1997; 45:26
  • Lau J.Y.W., Sung J.J.Y., Lee K.K.C., et al. Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers N Engl J Med 2000; 343:310-316
  • Marshall BJ, Warren JR et al. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311-5
  • Park CH, Joo YE, Kim HS, et al. A prospective, randomized trial comparing mechanical methods of hemostasis plus epinephrine injection to epinephrine injection alone for bleeding peptic ulcer. Gastrointest Endosc 2004; 60:173
  • Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple drug therapy for H.pylori eradication: a randomized trial. Ann Intern Med. 2007;146(8):556-63

 

Back to Top
explore
Reviewers

EXPERT REVIEWER:
Samir C. Grover, MD, MEd, FRCPC, Consultant, Division of Gastroenterology, St. Michael's Hospital, Assistant Professor, Department of Medicine, University of Toronto, ON Canada
.......................................... PHARMACY REVIEWER:
Peter Thomson, B.Sc. Pharm, Pharm.D., Clinical Pharmacist, Health Sciences Centre, Winnipeg, MB Canada

 
Copyright © 2011-2017 Innovate R&D
stroke

educate Are you a Healthcare professional or patient?

Healthcare Professionals would include: Physicians (MD,OD), Physician assistants, Nurses, Pharmacists,Allied Health Workers (PT, OT, SLP, etc), Chiropractors, Paramedics, Optometrists, Dentists, Podiatrists etc, and students within these disciplines.

educate ** You are required to register **

eDucate is committed to optimizing the delivery of health information across the Healthcare continuum. To this end eDucate uses a wide array of learning tools, including Webinars, Quick Review Charts, Graphs, Brochures, Videos and Slide Presentations.

Professional Membership Benefits include free access to all archived and upcoming Webinars:

educate DISCLAIMER: This website is owned and operated by The Innovate Research and Development LP (Innovate R&D). All references herein to Innovate R&D shall be deemed to include any subsidiary, affiliate, associate or successor corporation of Innovate R&D. By entering and using this site, you agree to the "Terms of Use"for this website. If you do not agree to these terms and conditions then exit from this site immediately. Although Innovate R&D updates this website regularly with material believed to be accurate at the time of posting, Innovate R&D does not guarantee the accuracy, completeness, timeliness or currency of the material and consequently Innovate R&D expressly disclaims any liability for errors or omissions in the material contained in the website. The Innovate R&D website and all contents are provided as-is, and all representations and warranties, express or implied, relating to the website or the content are disclaimed, including any implied warranty of merchantability, fitness for a particular purpose or non-infringement, as well as any warranty of quality, functionality, accuracy, currency, completeness, reliability, operability, use performance or absence of viruses. In no way or event will Innovate R&D or any party that has been involved in the creation, production, promotion and marketing be liable to you or any other party for perceived direct or indirect damages. You assume all responsibility and risk of loss resulting from the use of our website.